Joel Neal
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC 2220 MC 5826 Stanford, CA 94305 Tel Work (650) 725-3081 Fax (650) 498-5800
- Academic Offices
Personal Information Tel (650) 725-3081Alternate Contact Traci Foster Administrative Assistant Tel Work 650-725-3081Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Thoracic Oncology
- Lung Cancer
- Medical Oncology
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2010) |
| Medical Education: | Feinberg School of Medicine - Northwestern University IL (05/2004) |
| Fellowship: | Dana-Farber Cancer Institute MA (08/2010) |
| Residency: | Beth Israel Deaconess Medical Center MA (06/2007) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2007) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Non-small cell lung cancer (NSCLC) has historically been treated with combination chemotherapy. Over the last few years, molecular testing of NSCLC has revealed the presence of driving oncogenic mutations in a subset of tumors of adenocarcinoma histology, including EGFR, KRAS, and ALK. While chemotherapy is still effective for these patients, targeted therapies appear to be more specific with fewer side effects. For example, erlotinib treatment of EGFR mutant tumors results in better response rates and progression-free survival times than chemotherapy, and the investigational drug crizotinib is targeted against tumors harboring ALK translocations. My clinical and research interest is to apply evolving technologies to the diagnosis, characterization, and individualized treatment of NSCLC.
Clinical Trials
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations Recruiting
- Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR Recruiting
- Molecular Analysis of Thoracic Malignancies Recruiting
- A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Recruiting
- A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients with Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) Recruiting
Publications
- Current management of small cell lung cancer. Clin Chest Med. 2011; (4): 853-63
- One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer. Clin Cancer Res. 2011; (4): 638-9
- Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer. J Thorac Oncol. 2011; (11 Suppl 4): S1797-8
- AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther. 2010; (4): 487-95
- Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol. 2010; (1-2): 36-44
Help